In an effort to identify potential immunotherapeutic targets for the treatment of PCa with CAR T-cells, three antigens, namely Prostate-specific membrane antigen (PSMA), Prostate stem cell antigen (PSCA) and Epithelial cell adhesion molecule (EpCam CD326), are currently of clinical interest and part of clinical studies. The gene discussed is PSCA; the disease is posterior cortical atrophy.